# Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

> **NCT01344304** · NA · COMPLETED · sponsor: **Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group** · enrollment: 413 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Aprepitant / Fosaprepitant

## Key facts

- **NCT ID:** NCT01344304
- **Lead sponsor:** Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-11
- **Final completion:** 2015-04
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01344304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01344304, "Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01344304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*